시장보고서
상품코드
1429511

세계의 iPS 세포(유도만능줄기세포) 시장 보고서(2024년)

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

iPS 세포(유도만능줄기세포) 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상됩니다. 2028년에는 연평균 10.0%의 복합 성장률(CAGR)로 48억 1,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 만성 질환의 유병률 증가, 게놈 프로젝트의 확대, iPS 세포 유래 질환 모델 개발의 발전, 유전성 질환의 유병률 증가, 정부의 노력, 그리고 급속한 감염성 질환의 증가에 기인하는 것으로 추정됩니다. 예측 기간 동안 예상되는 주요 동향으로는 파킨슨병(PD)을 위한 다능성 줄기세포 개발, 전략적 제휴 및 파트너십, iPS 세포 유래 NK 세포 제작, 세포 치료용 iPS 세포(유도만능줄기세포) 개발, 핵심 기술 등이 있습니다. 재생의료 연구개발, iPS 세포 증식배지 배합, 맞춤형 iPS 세포 제작, 제 1형 당뇨병용 다능성 줄기세포 개발에 대한 투자 등이 있습니다.

iPS 세포(유도만능줄기세포) 시장은 주로 만성질환의 유병률 증가로 인해 크게 성장하고 있습니다. 심장병, 암, 뇌졸중, 당뇨병과 같은 질병은 모든 조직에서 유래하고 배아줄기세포를 모방하도록 유전자 변형된 iPS 세포에서 치료 수단을 찾을 수 있습니다. 만성질환 퇴치 파트너십(PFCD)의 보고서에 따르면, 조사 대상 미국인 1억 3,300만 명 중 45%가 적어도 한 가지 이상의 만성질환을 앓고 있는 것으로 나타났습니다. 이 보고서는 또한 미국 사망자 10명 중 7명, 약 170만 명이 만성질환으로 인한 사망으로 추정하고 있어 인공다능성 줄기세포 치료의 잠재적 영향력을 강조하고 있습니다. 만성질환 발생률의 증가는 인공다능성 줄기세포 치료 시장 수요 증가의 주요 요인으로 꼽힙니다.

iPS 세포(유도만능줄기세포) 시장의 성장에 기여하고 있는 것은 신경질환의 유병률 증가입니다. 신경계에 영향을 미치는 이러한 질환에는 급성 척수 손상, 알츠하이머병, 근위축성 측삭경화증(ALS) 등이 포함됩니다. 다능성 줄기세포는 질병 메커니즘을 연구하고, 약물 시험을 수행하고, 파킨슨병 및 알츠하이머병과 같은 신경 질환의 재생 치료법을 발전시킬 수 있는 귀중한 플랫폼을 제공합니다. 예를 들어, 알츠하이머병 협회에 따르면 2023년 65세 이상 미국인 670만 명이 알츠하이머병에 걸릴 것으로 추정되며, 2050년에는 1,270만 명에 달할 것으로 예측됩니다. 이러한 신경질환의 증가 추세는 iPS 세포(유도만능줄기세포) 시장의 중요한 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계의 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 시장 규모 실적과 성장, 2018-2023년
  • 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 iPS 세포(유도만능줄기세포) 시장, 유래 세포 유형별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 간세포
  • 섬유아세포
  • 케라티노사이트
  • 양막 세포
  • 기타 파생 세포
  • 세계의 iPS 세포(유도만능줄기세포) 시장, 용도별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 학술 연구
  • Drug Development & Discovery
  • 독성 스크리닝
  • 재생의료
  • 세계의 iPS 세포(유도만능줄기세포) 시장, 최종사용자별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원
  • 연구

제7장 지역 및 국가 분석

  • 세계의 iPS 세포(유도만능줄기세포) 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 iPS 세포(유도만능줄기세포) 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

  • iPS 세포(유도만능줄기세포) 시장 경쟁 상황
  • iPS 세포(유도만능줄기세포) 시장 기업 개요
    • FUJIFILM Holdings Corporation(FUJIFILM Cellular Dynamics, Inc)
    • Thermo Fisher Scientific, Inc
    • Takara Bio, Inc
    • Lonza Group AG
    • Astellas Pharma Inc

제31장 기타 주요 및 혁신적인 기업

  • ViaCyte, Inc
  • Ncardia
  • REPROCELL USA, Inc
  • Japan Tissue Engineering Co., Ltd
  • Merck KGaA
  • Cynata Therapeutics Limited
  • Dainippon Sumitomo Pharma
  • Shenzhen Bioscience
  • Shanghai Cell Therapy Group
  • Car-T Bio
  • JW therapeutics
  • Fosun Kite Biotechnology
  • Shanghai UniCar Therapy
  • Takaria Bio
  • SEED Biosciences SA

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 가능성 분석

제36장 부록

ksm 24.03.21

Induced pluripotent stem cells represent a regenerated form of stem cells, generated from existing adult cells, including hepatocytes, fibroblasts, keratinocytes, and neurons.

The principal derived cell types from induced pluripotent cells include hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes, as the liver's primary functional cells, play a crucial role in an extensive range of metabolic, endocrine, and secretory functions. These cells find applications in various fields such as academic research, drug development and discovery, toxicity screening, and regenerative medicine, and are utilized in sectors including hospitals and research laboratories.

The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports from The Business Research Company that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The induced pluripotent stem cell (ipsc) market size has grown rapidly in recent years. It will grow from $2.97 billion in 2023 to $3.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The expansion observed in the historical period can be attributed to the increasing healthcare expenditure, a surge in funding, growing awareness of the medicinal potential of stem cell products, the utilization of induced pluripotent stem cell (iPSC) based drug discovery, a rising demand for personalized medicine, and the cost-effective benefits of iPSC for drug discovery.

The induced pluripotent stem cell (ipsc) market size is expected to see rapid growth in the next few years. It will grow to $4.81 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of chronic diseases, the expansion of genomic projects, advancements in the development of iPSC-derived disease models, a rise in the prevalence of genetic diseases, government initiatives, and a rapid increase in technology. Major trends expected in the forecast period encompass the development of pluripotent stem cells for Parkinson's disease (PD), strategic collaborations and partnerships, the creation of iPSC-derived NK cells, the development of induced pluripotent stem cells (iPSC) for cell therapy, significant investment in regenerative medicine research and development, the formulation of iPSC expansion mediums, the creation of personalized iPSC, and the development of pluripotent stem cells for Type I diabetes.

The induced pluripotent stem cell market is witnessing significant growth, driven primarily by the increasing prevalence of chronic disorders. Conditions such as heart disease, cancer, stroke, and diabetes find treatment avenues in induced pluripotent stem cells, which are obtained from any tissue source and genetically modified to emulate embryonic stem cells. According to a report by the Partnership to Fight Chronic Disorder (PFCD), 45% of the 133 million Americans surveyed had at least one chronic disorder. The report also estimates that 7 out of 10 deaths in the USA, approximately 1.7 million, result from chronic disorders, emphasizing the potential impact of induced pluripotent stem cell treatment. The rising incidence of chronic diseases is a key driver for the increasing demand in the induced pluripotent stem cell treatment market.

Contributing to the growth of the induced pluripotent stem cell market is the escalating prevalence of neurological disorders. These disorders, affecting the nervous system, encompass conditions such as acute spinal cord injury, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells offer a valuable platform for studying disease mechanisms, conducting drug testing, and advancing regenerative therapies for neurological conditions such as Parkinson's and Alzheimer's disease. For instance, according to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older will have Alzheimer's in 2023, with projections reaching 12.7 million by 2050. This upward trend in neurological disorders is a significant driver for the induced pluripotent stem cell market.

Companies are actively seeking strategic partnerships and collaborations to expand their geographic reach and enhance product portfolios. Bristol Myers Squibb and Century Therapeutics, in January 2022, joined forces to develop iPSC-derived allogenic cell therapies targeting acute myeloid leukemia and multiple myeloma. Similarly, Evotec and Sernova announced a strategic partnership in May 2022 to develop iPSC-based beta cell replacement therapy for treating type 1 and type 2 diabetes.

Major players in the induced pluripotent stem cell market are intensifying their focus on introducing personalized induced pluripotent stem cells, exemplified by offerings such as Personal iPS. REPROCELL, a stem cell research company, launched Personal iPS in January 2021, providing a flexible and customizable service for reprogramming cells from various sources. The services include donor tissue collection, sample quarantine, derivation of primary cell lines, RNA-based iPSCs, and reprogramming technology.

In August 2021, catalant, a pharmaceutical company, acquired RheinCell Therapeutics GmbH, a move aimed at bolstering Catalent's presence in the cell and gene therapy sector and advancing therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH, based in Germany, specializes in developing human induced pluripotent stem cells (iPSCs) for next-generation cell therapies.

Major companies operating in the induced pluripotent stem cell (ipsc) market report are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc., Takara Bio, Inc., Lonza Group AG, Astellas Pharma Inc., ViaCyte, Inc., Ncardia, REPROCELL USA, Inc., Japan Tissue Engineering Co., Ltd., Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Banco de Cordon del Peru, CryoHoldco, CellSave Arabia, Life Cell, AmiCare, Cells4life, ReeLabs, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart

North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2023. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the induced pluripotent stem cell (ipsc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the induced pluripotent stem cell (ipsc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on induced pluripotent stem cell (ipsc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for induced pluripotent stem cell (ipsc)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The induced pluripotent stem cell (ipsc) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Other Derived Cell Types
  • 2) By Application: Academic Research; Drug Discovery And Toxicity Studies; Regenerative Medicine; Cell And Gene Therapy
  • 3) By End-User: Hospitals; Research Laboratories
  • Companies Mentioned: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc); Thermo Fisher Scientific, Inc; Takara Bio, Inc; Lonza Group AG; Astellas Pharma Inc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Induced Pluripotent Stem Cell (iPSC) Market Characteristics

3. Induced Pluripotent Stem Cell (iPSC) Market Trends And Strategies

4. Induced Pluripotent Stem Cell (iPSC) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Induced Pluripotent Stem Cell (iPSC) Market Size and Growth

  • 5.1. Global Induced Pluripotent Stem Cell (iPSC) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Induced Pluripotent Stem Cell (iPSC) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Induced Pluripotent Stem Cell (iPSC) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Induced Pluripotent Stem Cell (iPSC) Market Segmentation

  • 6.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hepatocytes
  • Fibroblasts
  • Keratinocytes
  • Amniotic Cells
  • Other Derived Cells
  • 6.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Academic Research
  • Drug Development And Discovery
  • Toxicity Screening
  • Regenerative Medicine
  • 6.3. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Research Laboratories

7. Induced Pluripotent Stem Cell (iPSC) Market Regional And Country Analysis

  • 7.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market

  • 8.1. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Induced Pluripotent Stem Cell (iPSC) Market

  • 9.1. China Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 9.2. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Induced Pluripotent Stem Cell (iPSC) Market

  • 10.1. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Induced Pluripotent Stem Cell (iPSC) Market

  • 11.1. Japan Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 11.2. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Induced Pluripotent Stem Cell (iPSC) Market

  • 12.1. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Induced Pluripotent Stem Cell (iPSC) Market

  • 13.1. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Induced Pluripotent Stem Cell (iPSC) Market

  • 14.1. South Korea Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 14.2. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Induced Pluripotent Stem Cell (iPSC) Market

  • 15.1. Western Europe Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 15.2. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Induced Pluripotent Stem Cell (iPSC) Market

  • 16.1. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Induced Pluripotent Stem Cell (iPSC) Market

  • 17.1. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Induced Pluripotent Stem Cell (iPSC) Market

  • 18.1. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Induced Pluripotent Stem Cell (iPSC) Market

  • 19.1. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Induced Pluripotent Stem Cell (iPSC) Market

  • 20.1. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market

  • 21.1. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 21.2. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Induced Pluripotent Stem Cell (iPSC) Market

  • 22.1. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Induced Pluripotent Stem Cell (iPSC) Market

  • 23.1. North America Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 23.2. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Induced Pluripotent Stem Cell (iPSC) Market

  • 24.1. USA Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 24.2. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Induced Pluripotent Stem Cell (iPSC) Market

  • 25.1. Canada Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 25.2. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Induced Pluripotent Stem Cell (iPSC) Market

  • 26.1. South America Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 26.2. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Induced Pluripotent Stem Cell (iPSC) Market

  • 27.1. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Induced Pluripotent Stem Cell (iPSC) Market

  • 28.1. Middle East Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 28.2. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Induced Pluripotent Stem Cell (iPSC) Market

  • 29.1. Africa Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 29.2. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape And Company Profiles

  • 30.1. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape
  • 30.2. Induced Pluripotent Stem Cell (iPSC) Market Company Profiles
    • 30.2.1. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific, Inc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Takara Bio, Inc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Lonza Group AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Astellas Pharma Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Induced Pluripotent Stem Cell (iPSC) Market Other Major And Innovative Companies

  • 31.1. ViaCyte, Inc
  • 31.2. Ncardia
  • 31.3. REPROCELL USA, Inc
  • 31.4. Japan Tissue Engineering Co., Ltd
  • 31.5. Merck KGaA
  • 31.6. Cynata Therapeutics Limited
  • 31.7. Dainippon Sumitomo Pharma
  • 31.8. Shenzhen Bioscience
  • 31.9. Shanghai Cell Therapy Group
  • 31.10. Car-T Bio
  • 31.11. JW therapeutics
  • 31.12. Fosun Kite Biotechnology
  • 31.13. Shanghai UniCar Therapy
  • 31.14. Takaria Bio
  • 31.15. SEED Biosciences SA

32. Global Induced Pluripotent Stem Cell (iPSC) Market Competitive Benchmarking

33. Global Induced Pluripotent Stem Cell (iPSC) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Induced Pluripotent Stem Cell (iPSC) Market

35. Induced Pluripotent Stem Cell (iPSC) Market Future Outlook and Potential Analysis

  • 35.1 Induced Pluripotent Stem Cell (iPSC) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Induced Pluripotent Stem Cell (iPSC) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Induced Pluripotent Stem Cell (iPSC) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제